Online inquiry

IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5558MR)

This product GTTS-WQ5558MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD33 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001082618.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 945
UniProt ID P20138
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5558MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7086MR IVTScrip™ mRNA-Anti-FAP, FAP-IL2v(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA FAP-IL2v
GTTS-WQ1791MR IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ADCT-402
GTTS-WQ10118MR IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LAG-525
GTTS-WQ15553MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ5399MR IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CD58-Fc
GTTS-WQ2434MR IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG 145
GTTS-WQ5933MR IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CK-301
GTTS-WQ12180MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MORAb-022
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW